August 23, 2016 10:50 AM EDT

Gilead tackles a big PhIII program for blockbuster hopeful filgotinib

John Carroll

Editor & Founder

Gilead $GILD has embarked on an ambitious Phase III program for filgotinib, one of the most closely-watched drugs now in the late-stage pipeline for rheumatoid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead tackles a big PhIII program for blockbuster hopeful filgotinib

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Gilead tack­les a big PhI­II pro­gram for block­buster hope­ful fil­go­tinib

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Gilead tackles a big PhIII program for blockbuster hopeful filgotinib